- Home
- TAL vs BBIO Comparison
TAL vs BBIO Comparison
Compare TAL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAL
- BBIO
- Stock Information
- Founded
- TAL 2003
- BBIO 2015
- Country
- TAL China
- BBIO United States
- Employees
- TAL N/A
- BBIO N/A
- Industry
- TAL Other Consumer Services
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TAL Real Estate
- BBIO Health Care
- Exchange
- TAL Nasdaq
- BBIO Nasdaq
- Market Cap
- TAL 4.7B
- BBIO 4.9B
- IPO Year
- TAL 2010
- BBIO 2019
- Fundamental
- Price
- TAL $9.85
- BBIO $23.72
- Analyst Decision
- TAL Strong Buy
- BBIO Strong Buy
- Analyst Count
- TAL 2
- BBIO 13
- Target Price
- TAL $14.20
- BBIO $46.92
- AVG Volume (30 Days)
- TAL 7.6M
- BBIO 1.6M
- Earning Date
- TAL 10-24-2024
- BBIO 11-12-2024
- Dividend Yield
- TAL N/A
- BBIO N/A
- EPS Growth
- TAL N/A
- BBIO N/A
- EPS
- TAL 0.12
- BBIO N/A
- Revenue
- TAL $1,836,617,000.00
- BBIO $217,765,000.00
- Revenue This Year
- TAL $46.60
- BBIO $3,690.39
- Revenue Next Year
- TAL $27.78
- BBIO N/A
- P/E Ratio
- TAL $83.40
- BBIO N/A
- Revenue Growth
- TAL 54.46
- BBIO 2209.77
- 52 Week Low
- TAL $7.35
- BBIO $21.62
- 52 Week High
- TAL $15.52
- BBIO $44.32
- Technical
- Relative Strength Index (RSI)
- TAL 42.28
- BBIO 41.49
- Support Level
- TAL $9.26
- BBIO $24.09
- Resistance Level
- TAL $12.14
- BBIO $27.57
- Average True Range (ATR)
- TAL 0.54
- BBIO 1.39
- MACD
- TAL -0.24
- BBIO -0.09
- Stochastic Oscillator
- TAL 20.49
- BBIO 17.20
About TAL TAL Education Group
TAL Education Group is a smart learning solutions provider in China. K-9 academic afterschool tutoring used to account for the majority of TAL's revenue before the regulatory changes in 2021 that imposed a nonprofit requirement on the business. After spinning off its K-9 academic afterschool tutoring business, TAL realigned its focus toward enrichment learning and content solutions.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.